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ABSTRACT
Areca-nut chewing has been well established as a major risk factor for oral cancer and precancerous diseases, whose pathophysiology has been associated with immune deterioration. Previous studies reported that areca nut extracts (ANE) affected the functionality
of lymphocytes and neutrophils in vitro. We recently showed that intraperitoneal administration of ANE modulated antigen-specific
immunity and promoted inflammatory reactions in ovalbumin (OVA)-sensitized mice. The objective of the present studies was to further
investigate the in vivo effect of ANE on T cell-mediated immune responses. In non-sensitized mice, a single oral dose of ANE (200 mg/kg)
markedly suppressed the production of interferon (IFN)-γ by splenocytes stimulated with the T cell mitogen concanavalin A, whereas
the expression of interleukin (IL)-2 or IL-4 was unaltered. In OVA-sensitized mice, daily administration of ANE (200 mg/kg) for 9 days
significantly suppressed the antigen-induced production of IFN-g by splenocytes and the serum level of antigen-specific IgM. Both the
cellularity and the metabolic activity of splenocytes were unaffected by the ANE treatment. Collectively, these results demonstrated that
oral administration of ANE modulated antigen-specific T cell responses. As IFN-g is a key cytokine involved in the activation of various
immunocompetent cells, ANE-mediated suppression of IFN-γ production may be a critical mechanism contributing to the immune
deterioration associated with areca-related oral diseases.
Key words: Areca nut, T-cell, interferon-γ, antigen-specific

INTRODUCTION
Areca quid (AQ) chewing is a popular habit in Taiwan,
India, and several other Asian countries with approximately
600 million chewers around the world(1). AQ chewing has
been well established as a major etiological factor for oral
cancer and precancerous lesions, including oral leukoplakia
and oral submucous fibrosis (OSF)(1,2). In addition to oral
diseases, AQ chewing is also a risk factor of hepatocellular carcinoma(3), suggesting that AQ chewing may cause
systemically deteriorating effects with a broad spectrum of
outcomes.
To date, the mechanisms responsible for the broad
spectrum of areca-associated toxic effects in AQ chewers
are mostly unclear. Clinical studies have documented that
immune dysfunction is closely associated with the pathophysiology of areca-related oral diseases(4,5). For example,
daily consumption of AQ has been shown correlated with
* Author for correspondence. Tel: +886-2-33661287;
Fax: +886-2-23661475; E-mail: tonyjan@ntu.edu.tw

the deregulation of humoral immunity in OSF patients(6). In
addition, cell-mediated immunity has been reported compromised in patients with areca-associated oral diseases(5).
T helper (Th) cells play a pivotal role in the host immunity against tumor formation(7). In particular, the Th1 cytokine interferon-gamma (IFN-γ) is a key cytokine involved in
both innate and acquired immunity, such as the promotion
of Th1 cell differentiation, the activation of natural killer
cells, cytotoxic T lymphocytes and macrophages, and the
stimulation of antibody production(8). Notably, immunohistochemical studies revealed that Th cells are the major
immunocompetent cells present in OSF tissues as evidenced
by an elevated ratio of CD4+ to CD8+ cells(9,10). However,
the expression of IFN-γ in the OSF tissues was suppressed,
indicating a down-regulation of T-cell functionality(10).
Concordantly, a decreased ability of peripheral blood mononuclear cells isolated from OSF patients to produce IFN-γ
was also observed(11). Collectively, these lines of evidence
demonstrates that the reactivity of T cells, such as the expression of IFN-γ, is down-regulated, which may contribute to
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the dysfunction of cellular immunity in areca-associated oral
diseases.
AQ is generally comprised of areca nut (Areca catechu),
piper betle leaf (Piper betle), and lime paste(1). As clinical
reports have shown alterations in many aspects of the immune
system in areca-associated oral diseases, the direct influence
of areca nut extract (ANE) ingredients on immune cells is
recently under intensive investigation. It has been reported
that ANE inhibited the phagocytosis and bactericidal
activity of neutrophils(12). The inhibition by areca ingredients on T-cell activation has also been demonstrated(13). We
previously showed that ANE inhibited the metabolic activity
and IFN-γ production by murine splenocytes in vitro(14). In
addition, ANE enhanced the production of inflammatory
cytokines in peripheral blood mononuclear cells(15). Intraperitoneal administration of ANE promoted inflammatory
reactions associated with delayed-type hypersensitivity and
modulated antigen-specific antibody production in ovalbumin (OVA)-sensitized mice(16). Together these studies
clearly demonstrate that lymphocytes are one of the sensitive
targets to ANE. However, evidence pertaining to the in vivo
effect of ANE on antigen-specific immunity remains limited
and to be further addressed.
The objective of the present study is to investigate the
effects of oral administration of ANE on antigen-induced
T cell responses. As AQ is consumed by chewing, the oral
route of administration is a more relevant mode of exposure
compared to the intraperitoneal route. We report here that oral
administration of ANE markedly attenuates the expression
of the Th1 signature cytokine IFN-γ in both non-sensitized
and antigen-sensitized mice. In addition, ANE suppresses
the serum production of antigen-specific immunoglobulin
M (IgM), substantiating the modulatory effect of ANE on
acquired immunity.

at least one week. The animal was housed in a temperature
(22 ± 2°C), humidity (50 ± 20%), and light-controlled environment (12 h light/dark cycle) with free access to standard
laboratory food and water.
III. ANE Administration Protocol
(I) Non-Sensitized Protocol
The mice were either left untreated (naïve; NA), or
administered by gavage with a single dose of ANE
(200 mg/kg; 0.2 mL/mouse) and/or H2O (vehicle; VH;
0.2 mL/mouse). The mice were sacrificed 3 h post drug
administration and their splenocytes were isolated for
further experiments (Figure 1A).
(II) OVA-Sensitized Protocol
The mice were either left untreated (NA), or sensitized
by intraperitoneal injection with a sensitization solution
containing OVA plus alum (100 μg/1 mg; OVA) on day 3.
The OVA-sensitized mice were administered once per day

(A) Non-sensitized protocol

Sacrifice
3h

Time 0 h

ANE and/or
VH (ddH2O)
(B) Ovalbumin (OVA)-sensitized protocol

MATERIALS AND METHODS
I. Reagents and Areca Nut Extract
All reagents were purchased from Sigma (St. Louis, MO,
USA) unless otherwise stated. Areca nuts were extracted
with water as previously described(17), and the extracts were
freeze-dried as ANE. The ANE has been confirmed endotoxin-free using a commercial Limulus amebocyte lysate
assay kit (Kinetic-QCL®; Lonza Walkersville Inc., Walkersville, MD, USA). Fetal bovine serum (FBS) and RPMI 1640
medium were from Hyclone (Logan, UT, USA). Reagents for
ELISA were from BD Biosciences (San Diego, CA, USA).
II. Animals
Male BALB/c mice, 5 - 6 weeks of age were purchased
from the Animal Breeding Center of the National Taiwan
University Hospital (Taipei, Taiwan). On arrival, the mice
were randomized, transferred to plastic cages containing a
saw-dust bedding (five mice per cage) and quarantined for

OVA/Albumin
Sensitization
Day 1

2

3

4

5

6

Sacrifice

7

8

9

ANE and/or VH (ddH2O)

Figure 1. Protocols for OVA-sensitization and ANE administration
to BALB/c mice. (A) In the non-sensitized protocol, male BALB/c
mice were randomly divided into the following groups: naïve (NA),
vehicle (VH; ddH 2O) and ANE-treated (200 mg/kg). The mice were
administered with VH and ANE by gavage. The splenocytes were
isolated 3 h after ANE administration for further experimentation.
(B) In the OVA-sensitized protocol, mice were randomly divided into
the following groups: naïve (NA), OVA-sensitized (OVA), vehicletreated and OVA-sensitized (VH), and ANE-treated (200 mg/kg) and
OVA-sensitized (ANE). Except for the NA group, mice were sensitized with OVA plus alum (100 μg/1 mg) on day 3. ANE and VH were
administered daily by gavage from day 1 - 9. All mice were sacrificed
3 h after the final drug treatment, and their serum and splenocytes
were obtained for further experimentation.
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with ANE (200 mg/kg; 0.2 mL/mouse; ANE) and/or H2O
(VH; 0.2 mL/mouse) by gavage from day 1 - 9. All mice
were sacrificed 3 h after the final dose of ANE, and their
serum and splenocytes were isolated for further experiments (Figure 1B). The animal experiments were approved
by the Institutional Animal Care and Use Committee of the
National Taiwan University.

washing with PBST, serum samples were added into wells
and incubated for 2 h. After washing, radish peroxidaseconjugated anti-mouse IgM was added and incubated for
1 h. The wells were washed again and a tetramethylbenzidine solution was added for colorimetric detection on a
microplate reader.

RESULTS

IV. Spleen Index
After sacrifice, the spleen of each mouse was dissected
out and weighed immediately. The spleen index was calculated as the spleen weight (mg) per body weight (g).
V. Cellularity of Splenocytes
Splenocytes were stained with rat anti-mouse CD4
conjugated with fluoroscein isothiocyanate (FITC), rat antimouse CD8 and B220 conjugated with PE-Cy5 antibodies
(BioLegend, San Diego, CA, USA) in phosphate-buffered
saline (PBS) containing 2% FBS. After washing, the
single cell fluorescence of 10,000 cells for each sample was
measured by a flow cytometer (BD FACSCalibur, San Jose,
CA, USA). Data were analyzed using the software Flowjo 5.7.
VI. Measurement of The Metabolic Activity of Splenocytes
Splenocytes were cultured in RPMI 1640 medium
supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin and 5% heat-inactivated FBS. In all cases, splenocytes were cultured at 37°C in 5% CO2. Splenocytes
(5 × 106 cells/mL) were cultured in quadruplicate in 96-well
plates (100 μL/well) and stimulated with concanavalin
A (ConA; 5 μg/mL) for 48 h or OVA (50 μg/mL) for 72 h.
The metabolic activity of splenocytes was determined by
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT) assay. Splenocytes were cultured 4 more h
in the presence of MTT (50 μg/mL) and the formed
formazan was dissolved with a lysis buffer (10% SDS in
N,N-demethylformamide) overnight in the dark. The plate
was read on a microplate reader at 570 nm using 630 nm as
the background reference.
VII. Cytokine Measurement
Splenocytes (5 × 106 cells/mL) were cultured in
quadruplicate in 48-well plates (300 μL/well) and stimulated
with ConA for 48 h or OVA for 72 h. After stimulation, the
supernatants from each well were quantified for interleukin
(IL)-2, IFN-γ and IL-4 by standard sandwich enzyme-linked
immunosorbent assay (ELISA) as previously described(14).
VIII. Measurement of OVA-Specific IgM
ELISA plates were coated with 0.05% OVA in coating
buffer (0.1 M NaHCO3) and blocked with 1% bovine serum
albumin in PBS containing 0.05% Tween-20 (PBST). After

I. ANE Attenuated IFN-γ Production by Splenocytes
Stimulated with ConA
T cell-derived cytokines participate in both humoral
and cell-mediated immune responses. We therefore examined the effect of ANE on the expression of IL-2, a pivotal
cytokine for T-cell clonal expansion, and IL-4 and IFN-γ
that are signature cytokines produced by Th1 and Th2 cells,
respectively, in non-sensitized mice. The dose (200 mg/kg)
of ANE was used according to previous reports showing the
in vivo effect of ANE to inhibit mast cell degranulation(18),
and to induce the sister chromatin exchange of bone marrow
chromosomes(19). Mice were sacrificed 3 h post a single dose
of ANE administration (Figure 1A), and their splenocytes
were stimulated with the T-cell mitogen concanavalin A
(ConA; 5 μg/mL) for 48 h to induced cytokine expression.
The production of IFN-γ was significantly attenuated by the
ANE treatment (Figure 2A), whereas IL-2 and IL-4 were
unaffected (Figure 2B and C). The effect of ANE on cytokine production may be due to alterations in T cell cellularity
and/or activity. Thus, the influence of ANE on the spleen
index, cellularity and the metabolic activity of splenocytes
was examined. The ANE treatment exerted no effect either
on the spleen index, cellularity (Table 1) or the metabolic
activity of splenocytes activated by ConA (Figure 2D).
II. ANE Attenuated Antigen-Specific IFN-γ Production
As ANE differentially suppressed ConA-induced
IFN-γ production by splenocytes of non-sensitized mice,
Table 1. Effect of ANE on spleen index and splenocyte cellularity
NA b

VH

ANE

3.7 ± 0.1

4.1 ± 0.2

4.0 ± 0.2

CD4+ Cells

25.9 ± 2.8

23.5 ± 1.8

24.7 ± 2.3

CD8+ Cells

9.7 ± 0.2

10.1 ± 0.5

10.2 ± 0.7

Spleen Index a
Splenocyte Cellularity (%)c

+

48.9 ± 1.0 48.7 ± 2.7 48.2 ± 1.7
B220 Cells
Spleen index was calculated as the spleen weight (mg) per body
weight (g). Data are expressed as mean ± SE of four samples and
are representative of three independent experiments.
b
NA: untreated; VH: vehicle-treated and OVA-sensitized and challenged and ANE: ANE-treated and OVA-sensitized and challenged.
c
T he percentage of CD4+, CD8+ and B220 + cells was determined
by flow cytometry. Data are expressed as mean ± SE of triplicate
samples pooled from three independent experiments.
a
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(A)

140

No Stimulation

(B)

ConA

100
80
60

0
VH

NA
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(D)
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1.4
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O.D. (570/650 nm)

120

IL-4 (pg/mL)

3

0
NA
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4

1
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2
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(C)

No Stimulation

5

IL-2 (ng/mL)

IFN-γ (ng/mL)

120

6

100
80
60
40

VH

ANE

No Stimulation
ConA

1.0
0.8
0.6
0.4
0.2

20
0

0.0
NA

VH

ANE

NA

VH
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Figure 2. Attenuation of IFN-g production by ANE administration in non-sensitized mice. Mice were treated with ANE as described in Figure
1A. Splenocytes (5 × 106 cells/mL) were stimulated with concanavalin A (ConA; 5 mg/mL) for 48 h. (A-C) The concentration of IFN-g, IL-2
and IL-4 in the supernatants was measured by ELISA. (D) The metabolic activity of viable cells was determined using the MTT assay. Data are
expressed as the mean ± SE of quadruplicate cultures. Results are representative of six independent experiments. *p < 0.05 compared to the VH
group.

we thus investigated whether ANE affected antigenspecific IFN-γ production. Splenocytes of OVA-sensitized
mice were re-stimulated with OVA (50 μg/mL) in culture
for 72 h to induce OVA-specific cytokine production. The
OVA re-stimulation successfully induced IFN-γ production
(Figure 3; OVA re-stimulation vs. no stimulation), which was
significantly attenuated by repeated administration of ANE
(Figure 3; ANE vs. VH). None of the metabolic activity of
splenocytes, the spleen index and cellularity was affected by
ANE treatment (data not shown).
III. ANE Attenuated OVA-Specific IgM Production
Antibody production is one of the hallmark responses
in the acquired immunity. Cytokines derived from Th cells
play a pivotal role in the activation of antibody-producing
B cells. As ANE administration attenuated OVA-specific
IFN-γ production, we therefore examined the effect of ANE
on the serum level of OVA-specific IgM, the major isotype
of immunoglobulin produced during the primary antibody

response. Our data showed a marked increase in the serum
OVA-specific IgM in OVA-sensitized mice indicating a
successful induction of antibody response, which was
significantly attenuated by repeated administration of ANE
(Figure 4).

DISCUSSION
Although immune dysfunction has been reported to be
associated with the pathophysiology of areca-related oral
diseases(5), evidence pertaining to the in vivo effect of areca
nut constituents on antigen-specific immunity is scarce. The
present study demonstrated that oral administration of ANE
markedly attenuated the production of IFN-γ by splenocytes
in both non-sensitized and antigen-sensitized mice, which is
in line with our previous report showing the suppression of
IFN-g production by splenocytes directly exposed to ANE
in vitro(14). As one of the major sources for IFN-g is Th1
cells, these results suggest that ANE differentially affects the

256
Journal of Food and Drug Analysis, Vol. 19, No. 3, 2011

functions of Th1 cells. Furthermore, we showed a marked
attenuation of the serum production of antigen-specific IgM
in OVA-sensitized mice treated with ANE. On the base
of these results, we postulated that the attenuation of the
acquired immunity by ANE may contribute to the clinical
observed immune dysfunction in patients with areca-related
oral diseases(5).
Immune responses mediated by the Th1 signature cytokines IFN-g are critical for the host defense against microbes
and tumor cells(20,21). IFN-γ can activate the killing activity

30

No Stimulation
OVA (50 µg/mL)

IFN-γ (ng/mL)

25
20
15
10
5
0
NA

OVA

VH

ANE

Figure 3. Attenuation of antigen-induced IFN-g production by ANE
administration in OVA-sensitized mice. Mice were treated with ANE
as described in Figure 1B. Splenocytes (5 × 106 cells/mL) were stimulated with OVA (50 mg/mL) for 72 h, and the concentration of OVAspecific IFN-γ in the supernatants was measured by ELISA. Data are
expressed as the mean ± SE of quadruplicate cultures. Results are
representative of four independent experiments. *p < 0.05 compared
to the matched VH group.

1.2

O.D. at 450 nm

1.0
0.8
0.6
0.4
0.2
0.0
NA (8)

OVA (15)

VH (20)

ANE (19)

Figure 4. Attenuation of the serum production of OVA-specific IgM
by ANE administration. Mice were treated with ANE as described
in Figure 1B. The serum titer of OVA-specific IgM was determined
by ELISA. Data are expressed as the mean ± SE of pooled data from
four independent experiments. The number of individual sample for
each group is indicated in the parenthesis. *p < 0.05 compared to the
matched VH group.

of natural killer cells, cytotoxic T cells and macrophages,
and promote the production of opsonizing and complementfixing antibodies that facilitate the phagocytosis of foreign
antigens(20,22). Lacking IFN-γ in knockout mice increased
the incidence of lymphoma, clearly indicating its pivotal role
in cancer immunosurveillance(21). Interestingly, T lymphocytes have been identified as the major immunocompetent
cells in the subepithelial connective tissue of OSF patients(9),
and the expression of IFN-γ in the oral cavity of OSF patient
was suppressed compared to normal controls(23). Furthermore, the ability of peripheral blood mononuclear cells to
produce IFN-γ was diminished in patients with oral leukoplakia, OSF, or head and neck cancers(11,24,25). Given the critical role of IFN-g in immunosurveillance, down-regulation
of the capability of Th1 cells to express IFN-g could be a
critical mechanism in the pathophysiology of areca-related
oral diseases. The disturbances of Th1 cell functions may
be caused by immunosuppressive mediators released by
tumor cells(26). Alternatively, as shown in the present studies,
contribution from the immunomodulatory effect caused by
areca constituents may be another critical mechanism to
suppress the functionality of T cells.
An increased production of autoantibodies and circulating immune complexes has been documented in patients
with areca-related oral diseases(27,28). Using the OVA model,
we showed that the production of antigen-specific IgM was
attenuated by oral administration of ANE, which is consistent
with our previous report showing a similar effect by intraperitoneal administration of ANE(16). It is currently unclear
whether ANE attenuated IgM via a direct effect on B cells
or an indirect mechanism mediated by cytokine suppression.
This issue requires further investigations.
Arecoline at the dose between 5 - 20 mg/kg has been
shown to affect splenic cellularity and antigen-specific
immune responses(30,31). However, the amount of arecoline
contained in our ANE is < 10 mg/mg of ANE (data not shown).
Hence, the dose of arecoline corresponding to 200 mg of
ANE/kg is < 2 mg/kg that is much lower than the reported
effective dose range of arecoline. Moreover, our data showed
that ANE administration did not affect splenic cellularity.
Therefore, it is apparent that arecoline may not play a major
role in the present studies. In addition to alkaloids, areca nuts
contain a significant amount of polyphenols, in particular
procyanidins(29). A growing body of evidence suggests that
procyanidins exhibit a broad spectrum of biological effects,
such as immunomodulation(32-34). For example, highly oligomeric procyanidins purified from Jatoba herb ameliorated
encephalomyelitis and collagen-induced arthritis in mice via
suppression of Th1 immunity, including suppression of IFN-γ
production and inhibition of macrophage maturation(33,34)
Therefore, procyanidins might be the active constituents
contributing to the immunosuppressive effect of ANE.
In summary, the present studies demonstrated that
oral administration of ANE attenuated the production of
IFN-γ and OVA-specific IgM. These results indicate that
areca nuts contain constituents that can be orally absorbed
and produce immunomodulatory effects. Areca-mediated
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down-regulation of IFN-γ production may be a potential
mechanism involved in the compromised acquired immunity
associated with areca-related oral diseases.
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